---
marp: true
theme: default
paginate: true
footer: "PHA 548 • Non-Benzodiazepine Sedative-Hypnotics • Medicinal Chemistry"
---

# Medicinal Chemistry of Non-Benzodiazepine Sedative-Hypnotics
## Z-Drugs and Related Hypnotics

---

## 1️⃣ Therapeutic Framing

### Clinical Problem
- Difficulty initiating sleep
- Middle-of-the-night awakening
- Desire to avoid long-acting sedation

### Medicinal Chemistry Objective
> Design hypnotics that **preserve BZD-site efficacy** while **controlling duration and accumulation** through structure-driven PK.

**Key distinction:**  
These agents are **not anxiolytics** — they are **hypnotics by design**.

---

## 2️⃣ Biological Target

- Same **GABA_A benzodiazepine allosteric site**
- Functional preference toward **α1 subunit**
- Positive allosteric modulation → ↑ frequency of channel opening

> This explains sedation **without strong anxiolysis**

---

## 3️⃣ Generalized Non-BZD Pharmacophore

**Abstracted pharmacophore (independent of scaffold):**

| Element | Function |
|------|---------|
| Aromatic system | π–π stacking (BZD Ring C mimic) |
| H-bond acceptor | Anchors in BZD site |
| Lipophilic tail | CNS penetration + duration tuning |

> **Diazepine ring is not required** if spatial geometry is preserved.

---

## 4️⃣ Structure–Activity Relationships (Pattern-Based)

| Structural Change | Predictable Outcome |
|------------------|--------------------|
| ↑ lipophilicity | ↑ onset, ↑ next-day effects |
| Block oxidation | ↑ duration |
| Polar substituent | ↓ duration |
| Short scaffold | Ultra-short hypnotic |
| α1 preference | Sedation > anxiolysis |

> SAR is used to **engineer duration**, not potency.

---

## 5️⃣ Physicochemical Properties → PK

| Property | Clinical Impact |
|------|----------------|
| Moderate lipophilicity | Rapid sleep onset |
| No active metabolites | Reduced hangover |
| Non-aromatic bulk | Faster clearance |

> Z-drugs succeed because **PK was prioritized over receptor novelty**.

---

## 6️⃣ Representative Drugs

### Zolpidem (Imidazopyridine)
- Rapid CNS entry
- CYP3A4 → inactive metabolites
- **Sleep onset agent**

### Zaleplon (Pyrazolopyrimidine)
- Aldehyde oxidase metabolism
- **Ultra-short duration**
- Useful for middle-of-night dosing

### Eszopiclone (Cyclopyrrolone)
- More polar → longer duration
- **Sleep maintenance**
- Dysgeusia = structure-linked adverse effect

---

## 7️⃣ Therapeutic Decision Matrix

| Clinical Need | Structural Preference |
|-------------|----------------------|
| Sleep onset | High lipophilicity, short t½ |
| Middle-of-night | Ultra-short, rapid clearance |
| Sleep maintenance | Moderate duration |
| Elderly | Avoid excess lipophilicity |

---

## 8️⃣ Common Pitfalls (Explicit)

❌ “Z-drugs are non-addictive”  
❌ “Z-drugs don’t cause amnesia”  
❌ “Z-drugs are safer for all patients”

✅ **Correct:**  
Z-drugs trade **duration control** for **retained GABAergic risk**.

---

## 9️⃣ Take-Home Message

> *Non-benzodiazepine hypnotics achieve clinical selectivity through pharmacophore preservation and structure-driven pharmacokinetics rather than novel receptor targets.*
